Mr. Rao's inducement awards were granted effective as of July 1, 2024. Mr. Rao's inducement awards consist of (i) a non-statutory stock option to purchase up to 20,000 shares of the Ocular's common stock at a per share exercise price equal to the closing price of Ocular's common stock on The Nasdaq Global Market on July 1, 2024, and (ii) a restricted stock unit award representing the right to receive 6,666 shares of Ocular's common stock. The stock option has a ten-year term and is scheduled to vest over fo ...

WORLD CLASS RETINA EXPERTISE AXPAXLI Has Demonstrated Proof-of-Concept in Three Phase 1 trials wAMD Trials Demonstrated Monotherapy Proof-ofConcept and Potential Best–in–class Durability Phase 1 Australia Trial1: Monotherapy Activity Month 9 CSFT: 244µm BCVA: 81 letters (20/25) Month 6 CSFT: 239µm BCVA: 80 letters (20/25) Month 2 CSFT: 236µm BCVA: 74 letters (20/30) Baseline CSFT: 484µm BCVA: 56 letters (20/80) Treatment naïve & experienced patients Treatment naïve & experienced patients Patients received n ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Investor Day Conference Call June 13, 2024 2:00 PM ET Company Participants Bill Slattery - Vice President, Investor Relations Pravin Dugel - Executive Chairman, President and CEO Jeff Heier - Chief Scientific Officer Peter Kaiser - Chief Development Officer Nadia Waheed - Chief Medical Officer Barry Kuppermann - Steinert Professor and Chair, Department, Ophthalmology and Director, Gavin Herbert Eye Institute, UC, Irvine Dilsher Dhoot - Retina Consultants of America Don ...

About Ocular Therapeutix, Inc. 151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7, 2024 48-week HELIOS NPDR results show 23.1% of patients in AXPAXLI arm experienced ≥2-step DRSS improvement with no patients experiencing worsening of DRSS or vision threatening complications "2024 has been a time of significant accomplishment for Ocular. To support our mission to become a leader in retinal care, we successfully assembled a 'Retina Dr ...

Ocular's Investor Day will also include KOL roundtable discussions followed by a live Q&A session. In-person attendees are invited to join Ocular leadership and the participating KOLs for a networking reception to conclude the event. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Company's website at investors.ocutx.com. A replay of the webcast will be archived for at least 30 days following the presentation. About Baruch D. Kuppermann, ...

Shidlovski Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company developing innovative eye treatment therapies. OCUL already offers a commercial product called Dextenza for post-surgical ocular inflammation and pain and ocular itching due to allergic conjunctivitis. The drug is a market success with a net product revenue of $57.9 million in 2023. OCUL's pipeline includes Axpaxli, an axitinib intravitreal implant in phase 3 trials for wet age-related macular degeneration (wet AMD) and phase 1 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36554 Ocular Therapeutix, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdi ...

Exhibit 99.1 "Ocular's excellent progress in 2024 has put the Company on track to becoming a leading retinal care company. We have substantially enriched the organization with the appointment of recognized leaders in retinal care and clinical development; have completed a successful financing of $325 million in gross proceeds from existing and new top-tier healthcare investors; and have progressed our Phase 3 program for AXPAXLI™ in wet AMD," said Pravin U. Dugel, MD, Executive Chairman, President and Chief ...

BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it has agreed to grant inducement awards to (i) its newly appointed Vice President, Head of Programming & Data Ope ...

BEDFORD, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that it will participate at two investor conferences in May: Citizens JMP Life Sciences Conference Fire ...